Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global companion diagnostics market size stood at a value of USD 2.1 billion in 2020. The companion diagnostics market is expected to achieve USD 8.4 billion by 2026, growing at a CAGR of 26% between the forecast period of 2021 and 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The companion diagnostics industry is anticipated to grow significantly during the forecast period due to an increase in R&D of targeted therapies for cancer, along with the increasing demand for personalised medicine.
A companion diagnostic is a medical in-vitro device that offers data for the secure and efficient use of a drug and determines its applicability to a specific person. This diagnostic test enables a medical specialist to determine whether a specific therapeutic product helps patients or not, outweighing any severe potential side effects or hazards. The industry can be divided based on its product and services into assay kits and reagents, and software and services.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised based on its end-use into:
The industry can be divided based on its technology as polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among others.
The industry can be divided based on indication as:
The EMR report looks into the regional companion diagnostics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increased popularity of personalised medicines, rising cases of adverse drug reactions (ADRs) and higher number of unmet needs for treating cancer are the driving factors, accelerating the growth of the companion diagnostics market. An increase in healthcare expenditure, globally, and technological advancements in diagnostic techniques are propelling the positive growth of the industry. With rising awareness, particularly in developing economies, along with the discovery of new biomarkers for diverse conditions, the industry is witnessing a further growth. The growth of the companion animal diagnostics market will also propel the growth of the overall companion diagnostics industry. The cases of cancer is expected drive the growth of the companion diagnostics industry in the oncology segment. The approval of companion diagnostics by government agencies like the FDA is expected to drive the growth of the industry. Unfavourable reimbursement policies in some countries may affect the companion diagnostics market growth during the forecast period.
The report presents a detailed analysis of the following leading companies in the global companion diagnostics market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product & Service, Technology, Indication, End Use, Region |
Breakup by Product & Service | Assay Kits and Reagents, Software and Services |
Breakup by Technology | Polymerase Chain Reaction, Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing, Other Technologies |
Breakup by Indication | Oncology, Neurology |
Breakup by End Use | Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Other End Users |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Biomérieux SA, Danaher Corporation, Illumina, Inc., Myriad Genetics, Inc, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Companion Diagnostics Market Analysis
8.1 Key Industry Highlights
8.2 Global Companion Diagnostics Historical Market (2018-2022)
8.3 Global Companion Diagnostics Market Forecast (2023-2028)
8.4 Global Companion Diagnostics Market by Product and Service
8.4.1 Assay Kits and Reagents
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Software and Services
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.5 Global Companion Diagnostics Market by Technology
8.5.1 Polymerase Chain Reaction
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Immunohistochemistry
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 In Situ Hybridization
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Next-Generation Sequencing
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Other Technologies
8.6 Global Companion Diagnostics Market by Indication
8.6.1 Oncology
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.1.4 Breakup by Type
8.6.1.4.1 Breast Cancer
8.6.1.4.2 Lung Cancer
8.6.1.4.3 Colorectal Cancer
8.6.1.4.4 Melanoma
8.6.1.4.5 Gastric Cancer
8.6.1.4.6 Other Cancers
8.6.2 Neurology
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.2.4 Breakup by Type
8.6.2.4.1 Infectious Diseases
8.6.2.4.2 Other Indications
8.7 Global Companion Diagnostics Market by End Use
8.7.1 Pharmaceutical and Biopharmaceutical Companies
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Reference Laboratories
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Other End Users
8.8 Global Companion Diagnostics Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 F. Hoffmann-La Roche Ltd
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Agilent Technologies, Inc.
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Thermo Fisher Scientific, Inc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Abbott Laboratories, Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Illumina, Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Companion Diagnostics Market: Key Industry Highlights, 2018 and 2028
2. Global Companion Diagnostics Historical Market: Breakup by Product and Service (USD Million), 2018-2022
3. Global Companion Diagnostics Market Forecast: Breakup by Product and Service (USD Million), 2023-2028
4. Global Companion Diagnostics Historical Market: Breakup by Technology (USD Million), 2018-2022
5. Global Companion Diagnostics Market Forecast: Breakup by Technology (USD Million), 2023-2028
6. Global Companion Diagnostics Historical Market: Breakup by Indication (USD Million), 2018-2022
7. Global Companion Diagnostics Market Forecast: Breakup by Indication (USD Million), 2023-2028
8. Global Companion Diagnostics Historical Market: Breakup by End Use (USD Million), 2018-2022
9. Global Companion Diagnostics Market Forecast: Breakup by End Use (USD Million), 2023-2028
10. Global Companion Diagnostics Historical Market: Breakup by Region (USD Million), 2018-2022
11. Global Companion Diagnostics Market Forecast: Breakup by Region (USD Million), 2023-2028
12. North America Companion Diagnostics Historical Market: Breakup by Country (USD Million), 2018-2022
13. North America Companion Diagnostics Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Europe Companion Diagnostics Historical Market: Breakup by Country (USD Million), 2018-2022
15. Europe Companion Diagnostics Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Asia Pacific Companion Diagnostics Historical Market: Breakup by Country (USD Million), 2018-2022
17. Asia Pacific Companion Diagnostics Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Latin America Companion Diagnostics Historical Market: Breakup by Country (USD Million), 2018-2022
19. Latin America Companion Diagnostics Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Middle East and Africa Companion Diagnostics Historical Market: Breakup by Country (USD Million), 2018-2022
21. Middle East and Africa Companion Diagnostics Market Forecast: Breakup by Country (USD Million), 2023-2028
22. Global Companion Diagnostics Market Structure
The global companion diagnostics market attained a USD 2.1 billion in 2020.
In the forecast period 0f 2021-2026, the market is projected to grow at a CAGR of 26%.
The major drivers of market such as technological advancements in diagnostic techniques, increasing popularity of personalised medicines, approval of companion diagnostics by government agencies, discovery of new biomarkers for diverse conditions, growth of the companion animal diagnostics market, rising cases of cancer and higher number of unmet needs for treating cancer are driving the industry growth.
Increase in healthcare expenditure, globally, and rising cases of adverse drug reactions (ADRs) are the key trends propelling the market growth.
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the major regions in the market.
The leading products and services are assay kits and reagents and software and services.
Major technologies of the product are polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among other technologies.
The significant indications of the product in the industry are oncology and neurology. Oncology is sub-divided into breast cancer, lung cancer, colorectal cancer, melanoma, and gastric cancer, among other cancers whereas neurology is further divided into infectious diseases and other indications.
The major end-use segments for the market include pharmaceutical and biopharmaceutical companies and reference laboratories, among other end users.
The major players in the market are F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Biomérieux SA, Danaher Corporation, Illumina, Inc., and Myriad Genetics, Inc among others.
The global companion diagnostics market attained a value of USD 2.1 billion in 2020 driven by the increasing popularity of personalised medicines. Aided by the increasing in healthcare expenditure, globally, and technological advancements in diagnostic techniques, the market is expected to further grow at CAGR of 26% in the forecast period of 2021-2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. On the basis of products and services, the market is divided into assay kits and reagents and software and services. Based on the technologies, the industry can be segmented into polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among other technologies. On the basis of indication, the market is bifurcated into oncology and neurology. Oncology is sub-divided into breast cancer, lung cancer, colorectal cancer, melanoma, and gastric cancer, among other cancers whereas neurology is further divided into infectious diseases and other indications. Based on end-use sector, the market can be categorised into pharmaceutical and biopharmaceutical companies and reference laboratories, among other end users. The major regional markets for the product are North America, Latin America, Europe, the Asia Pacific, and the Middle East and Africa. The key players in the above industry include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Biomérieux SA, Danaher Corporation, Illumina, Inc., and Myriad Genetics, Inc among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.